A Phase 2 interventional study of Celery Seed and Placebo in Metabolic Syndrome, sponsored by University of Guadalajara. Recruiting at 1 site in Mexico. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by University of Guadalajara · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Metabolic Syndrome by University of Guadalajara — 3 open to participants now, 3 under way, none of them phase 3. Metabolic Syndrome · University of Guadalajara.
Among the 13 studies in Metabolic Syndrome by University of Guadalajara, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 7 in phase 2, and was the 11th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →3 of the 13 studies in Metabolic Syndrome by University of Guadalajara are open now, in 1 country. Recruiting first, the newest first:
University of Guadalajara · Sites in Mexico
Ages 18–60
University of Guadalajara · Sites in Mexico
Ages 30–60
By country, each count listing its studies:
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 2
First in 2012; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 28 across the 13 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Guadalajara is the lead sponsor of 95 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Metabolic Syndrome by University of Guadalajara, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Metabolic Syndrome (MS) is a cluster of cardiometabolic risk factors, which include abdominal obesity, hyperglycemia, dyslipidemia, and high blood pressure. MS is a global health problem, it represents a risk factor for the progression of cardiovascular disease, which constitute the main cause of mortality in the world and in Mexico. The current treatment involves lifestyle changes and pharmacological treatment for each of the components of MS, however, there is no single approved treatment to control all components. Celery seed (Apium graveolens L.) from the Apiaceae family contains the flavonoids apigenin and luteolin; essential oils such as d-limonene, selinene and phthalides such as 3-n-butylphthalide. Thanks to its bioactive components, celery seed has proven to be effective in treating individual MS disorders; however, most studies are in animal models and there are no clinical studies that evaluate its effectiveness on all components of the system. MS, insulin sensitivity and insulin secretion so it could appear as a new, safe and effective complementary therapy for the treatment of MS.
The aim of this study is to evaluate the effect of celery seed on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.
A randomized, double-blind controlled clinical trial in 28 patients between 30 to 60 years of age with a diagnosis of MS according to the International Diabetes Federation (IDF) criteria without treatment and whether they voluntary accept participating and signing the informed consent.
Patients with one or more of the following criteria will be excluded: History of kidney, thyroid or liver disease; systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, fasting glucose ≥ 126 mg/dL, triglycerides ≥ 500 mg/dL, total cholesterol ≥240 mg/dL; pregnancy or lactation; consumption of medications or supplements with effects on the study variables.
Patients included, may be withdrawn from the study if they meet any of the following conditions: Withdrawal of the informed consent, treatment adherence \<80%, severe adverse reaction, intolerance or hypersensitivity to celery seed or placebo.
They will be assigned randomly two groups of 14 patients; one of the groups will receive 75 mg of celery seed twice at day (before breakfast and dinner) for 12 weeks.
The other group will receive homologated placebo (calcined magnesia) twice at day (before breakfast and dinner) for 12 weeks.
Waist circumference, blood pressure, fasting blood glucose, serum triglycerides and serum HDL cholesterol will be evaluated before and after intervention in both groups. Insulin sensitivity (Matsuda index), total insulin secretion (it is the result of the ratio between the area under the curve (AUC) of insulin in a 2-h OGTT and the AUC of glucose in a 2-h OGTT) and First phase of insulin secretion (Stumvoll index), will be calculated from the concentration of glucose and insulin obtained from an Oral Glucose Tolerance Test.
This protocol It´s already approved by the local ethics committee and written informed consent it´s going to be obtained from all volunteers.
Statistical analysis will be presented through measures of central tendency and dispersion, mean and deviation standard for quantitative variables; frequencies and percentage for qualitative variable. The analysis between groups (independent samples) will be analyzed using the Mann-Whitney U test for quantitative variables and the X2 test or Fisher's exact test for qualitative variables. The intragroup analysis (two related samples) will be performed using the Wilcoxon range test for quantitative variables. Statistical significance will be considered with a p\<0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of metabolic syndrome (MS) according to the IDF criteria: waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
14 patients to receive homologated intervention capsule (celery seed 150 mg) one capsule with 75 mg of celery seed, every 12 hours (before breakfast and before dinner) along 12 weeks.
Drug: Celery Seed
14 patients to receive homologated placebo capsule (calcinated magnesia) one capsule with calcinated magnesia, every 12 hours (before breakfast and before dinner) along 12 weeks.
Drug: Placebo
Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Also known as: Apium graveolens Leen
Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Also known as: Calcined magnesia
Waist Circumference (WC)
Waist Circumference will be evaluated at baseline and week 12 by World Health Organization technique
Time frame: Baseline to week 12 (end of intervention)
Systolic Blood Pressure (SBP)
Systolic Blood Pressure (SBP) will be measured at baseline and week 12 with a digital sphygmomanometer three times in each arm to get an average
Time frame: Baseline to week 12 (end of intervention)
Diastolic Blood Pressure (DBP)
Diastolic Blood Pressure (DBP) will be measured at baseline and week 12 with a digital sphygmomanometer three times in each arm to get an average
Time frame: Baseline to week 12 (end of intervention)
High-Density Lipoprotein (HDL-c)
High density lipoprotein (HDL-c) level will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get c-HDL level
Time frame: Baseline to week 12 (end of intervention)
Fasting Blood Triglycerides Concentration (TG)
Fasting Blood Triglycerides Concentration (TG) level will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get triglycerides concentration
Time frame: Baseline to week 12 (end of intervention)
Fasting Serum Glucose (FSG)
The Fasting Serum Glucose (FSG) levels will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get fasting glucose level
Time frame: Baseline to week 12 (end of intervention)
Insulin Sensitivity (Matsuda Index)
Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index to get insulin sensitivity
Time frame: Baseline to week 12 (end of intervention)
Total Insulin Secretion
Total insulin secretion will be calculated at baseline and week 12. It is the result of the ratio between the AUC of insulin in a 2-h OGTT and the AUC of glucose in a 2-h OGTT. It allows estimating the proportion of total insulin secretion in relation to plasma glucose concentration.
Time frame: Baseline to week 12 (end of intervention)
First Phase of Insulin Secretion (Stumvoll Index)
The first phase if insulin secretion will be calculated at baseline and week 12 with Stumvoll index to get first phase of insulin secretion
Time frame: Baseline to week 12 (end of intervention)
Body weight
Body weight will be measured at baseline and week 12 with a bioimpedance analysis
Time frame: Baseline to week 12 (end of intervention)
Body Mass Index (BMI)
Body Mass Index (BMI) will be calculated at baseline and week 12 with the Quetelet index formula
Time frame: Baseline to week 12 (end of intervention)
Body Fat Percentage
Body fat percentage will be measured at baseline and week 12 with a bioimpedance analysis
Time frame: Baseline to week 12 (end of intervention)
Total Cholesterol (TC)
Total Cholesterol (TC) level will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get total cholesterol level
Time frame: Baseline to week 12 (end of intervention)
Low Density Lipoprotein (LDL-c)
Low Density Lipoprotein (LDL-c) level will be calculated at baseline and week 12 with Friedewald formula to get LDL-c level
Time frame: Baseline to week 12 (end of intervention)
Very Low Density Lipoprotein (VLDL)
Very Low Density Lipoprotein (VLDL) level will be calculated at baseline and week 12 with triglycerides concentration/5 formula to get VLDL level
Time frame: Baseline to week 12 (end of intervention)
Concentration of Blood Aspartate Aminostransferase (AST)
Concentration of Blood Aspartate Aminostransferase (AST) level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get AST level
Time frame: Baseline to week 12 (end of intervention)
Alanine Aminotransferase (ALT)
Concentration of Blood Alanine Aminostransferase (ALT) level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get ALT level
Time frame: Baseline to week 12 (end of intervention)
Creatinine
Concentration of creatinine level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get creatinine level
Time frame: Baseline to week 12 (end of intervention)
Uric Acid
Concentration of uric acid level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get uric acid level
Time frame: Baseline to week 12 (end of intervention)
Incidence of treatment-Emergent Adverse Events
Incidence of treatment-Emergent Adverse Events of celery seed or placebo will be identified by clinical evaluation from baseline week to week 12 with continuous surveillance
Time frame: Baseline to week 12 (end of intervention)
Tolerability to treatment
Tolerability to treatment of celery seed or placebo will be identified by clinical evaluation from baseline week to week 12 with continuous surveillance
Time frame: Baseline to week 12 (end of intervention)
Started May 2023 (actual). Primary completion is estimated for Jun 2025, 25 months after the start.
Of 28 non-industry phase 2 interventional studies under Metabolic Syndrome, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 62. This study's planned 25 months is below that.
Counting every sponsor, half of 31 studies reached it within 29 months; a quarter within 25 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Guadalajara